Professor, Oncology, Mayo Medical School
Radiation Oncology
Dr. Thomas M. Pisansky, MD
|
|
Give Review
Thomas Pisansky works in the field of Radiation Oncology. He graduated from University of Minnesota Medical School. University of Minnesota Medical School has a rank of 40 in research and a 10 in primary care He over the years received 1 awards: "Regional Top Doctor". Doctor Thomas M. Pisansky, MD is also a published doctor. He has 52 paper published. The most recent paper is: Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy. He is registered with Medicare.
Publications
- Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate Cancer after salvage radiation therapy.
- Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate Cancer: the Radiation Therapy Oncology Group [0831] randomized clinical trial.
- Multimodality therapy including surgical resection and intraoperative electron radiotherapy for recurrent or advanced primary carcinoma of the urinary Bladder or ureter.
- PSA screening in men newly diagnosed with colorectal Cancer: each according to his group's means?
- Lack of Association between COX-2 Staining Level and Biochemical Recurrence Following Salvage Radiation Therapy for Recurrent Prostate Cancer.
- Long-term outcomes of radiotherapy for stage II testicular seminoma-the Mayo Clinic experience.
- Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast Cancer.
- Dosimetric effect of interfractional needle displacement in Prostate high-dose-rate brachytherapy.
- Long-Term Outcomes After Maximal Surgical Resection and Intraoperative Electron Radiotherapy for Locoregionally Recurrent or Locoregionally Advanced Primary Renal Cell...
- Long-Term Results of a Phase II Trial of Ultrasound-Guided Radioactive Implantation of the Prostate for Definitive Management of Localized AdenoCarcinoma of the Prosta...
- Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate Cancer.
- Randomized, double-blinded, placebo-controlled crossover trial of treating erectile dysfunction with sildenafil after radiotherapy and short-term androgen deprivation ...
- Longitudinal Quality-of-Life Analysis of RTOG 94-05 (Int 0123):A Phase III Trial of Definitive Chemoradiotherapy for Esophageal Cancer.
- Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate Cancer: dose-response analysis.
- Evaluation of ki-67 staining levels as an independent biomarker of biochemical recurrence after salvage radiation therapy for prostate Cancer.
- Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate Cancer.
- Radiotherapy and adjuvant trastuzumab in operable breast Cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.
- A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate Cancer.
- High-dose-rate brachytherapy in the curative treatment of patients with localized prostate Cancer.
- Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate Cancer treated with adjuvant or salvage radiotherapy.
- Predicting the outcome of salvage radiation therapy for recurrent prostate Cancer after radical prostatectomy.
- Advanced prostate Cancer and postoperative radiotherapy.
- Multi-institutional analysis of long-term outcome for stages T1-T2 prostate Cancer treated with permanent seed implantation.
- Nadir Prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.
- External-beam radiotherapy for localized prostate Cancer.
- Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate Cancer patients treated with external beam radiation therapy a...
- Salvage radiotherapy for isolated Prostate specific antigen increase after radical Prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring...
- Comparison of biochemical failure definitions for permanent Prostate brachytherapy.
- Increasing external beam dose for T1-T2 prostate Cancer: effect on risk groups.
- PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate Cancer: a multi-institutional analysis.
- Prostate position relative to pelvic bony anatomy based on intraprostatic gold markers and electronic portal imaging.
- Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast Cancer.
- Health-related quality of life in men receiving Prostate brachytherapy on RTOG 98-05.
- External beam radiotherapy as curative treatment of prostate Cancer.
- Definitions of biochemical failure that best predict clinical failure in patients with prostate Cancer treated with external beam radiation alone: a multi-institutiona...
- Patient-specific daily pretreatment setup protocol using electronic portal imaging for radiation therapy.
- Long-term follow-up of radiotherapy for prostate Cancer.
- Prostate volume measurement by transrectal ultrasound and computed tomography before and after permanent Prostate brachytherapy.
- Prostate volume before and after permanent Prostate brachytherapy in patients receiving neoadjuvant androgen suppression.
- Radioactive seed migration to the chest after transperineal interstitial Prostate brachytherapy: extraprostatic seed placement correlates with migration.
- Selective identification of different brachytherapy sources, ferromagnetic seeds, and fiducials in the Prostate using an automated seed sorting algorithm.
- Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate Cancer in patients undergoing radiation treatment for prostate Cancer.
- Technical aspects of daily online positioning of the Prostate for three-dimensional conformal radiotherapy using an electronic portal imaging device.
- Long-term multi-institutional analysis of stage T1-T2 prostate Cancer treated with radiotherapy in the PSA era.
- Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast Cancer.
- Adjuvant external radiation therapy following radical prostatectomy for node-negative prostate Cancer.
- Radiation exposure to operating room personnel during transperineal interstitial permanent Prostate brachytherapy.
- Electronic and film portal images: a comparison of landmark visibility and review accuracy.
- The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate Carcinoma.
- INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal Cancer: high-dose versus standard-dose radiation therapy.
- Evaluation of Serum Calcium as a Predictor of Biochemical Recurrence following Salvage Radiation Therapy for Prostate Cancer.
Schools
University Of Minnesota Medical School
Hennepin County Med Center
Mayo Clinic Rochester
Procedures Preformed
- Thoracentesis
Conditions Treated
- AdRenal Gland Cancer
- Anemia
- Bladder Cancer
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Oncology
- Radiation Oncology
Accepted Insurances
- Choice Plus POS II
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Choice Care PPO
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Options PPO
Awards
- Regional Top Doctor
Education
-
Mayo School of Graduate Medical Education -
Hennepin County Medical Center -
University of Minnesota Medical School
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1235118415 | |
| NPPES Provider LastName | PISANSKY | |
| NPPES Provider FirstName | THOMAS | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 66.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1235118415 |
| Last Name Of The Provider | PISANSKY |
| First Name Of The Provider | THOMAS |
| View All |
Similar Doctors
|
|
Dr. Robert L. Foote, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Daniel J. Ma, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ryan K. Funk, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Larry R. Past, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kenneth W. Merrell, MD
This Doctor is OpenDoctor Recommended.
|